Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Capital Expenditures (2016 - 2025)

Heron Therapeutics' Capital Expenditures history spans 14 years, with the latest figure at $208000.0 for Q2 2025.

  • For Q2 2025, Capital Expenditures changed N/A year-over-year to $208000.0; the TTM value through Dec 2025 reached $317000.0, down 84.99%, while the annual FY2025 figure was $317000.0, 81.42% down from the prior year.
  • Capital Expenditures reached $208000.0 in Q2 2025 per HRTX's latest filing, up from $109000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.5 million in Q3 2021 to a low of $45000.0 in Q3 2022.
  • Average Capital Expenditures over 5 years is $486125.0, with a median of $356000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: plummeted 97.06% in 2022, then surged 1662.22% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $390000.0 in 2021, then increased by 6.15% to $414000.0 in 2022, then plummeted by 39.61% to $250000.0 in 2023, then surged by 155.2% to $638000.0 in 2024, then plummeted by 67.4% to $208000.0 in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Capital Expenditures are $208000.0 (Q2 2025), $109000.0 (Q1 2025), and $638000.0 (Q4 2024).